CD34 and cancer: A significant proportion of cancer patients eligible for ASCT fails to mobilize a sufficient number of CD34+ hematopoietic stem/progenitor cells due to various pre-mobilization (predictive) factors such as prior treatment with stem cell toxic drugs, underlying disease, age, prior radiotherapy and BM involvement.